Epitopic overload at the site of injection may result in suppression of the immune response to combined capsular polysaccharide conjugate vaccines

Vaccine

Volumn 17, Issue 2, 1999, Pages 126-133

  Fattom, Ali ^a   Cho, Yun Hee ^a   Chu, Chiayung ^b   Fuller, Steven ^a   Fries, Louis ^a   Naso, Robert ^a  

^a Nabi Biopharmaceuticals   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Combination vaccines; Conjugate vaccines; Immune response; Interference

Indexed keywords

BACTERIAL POLYSACCHARIDE; CARRIER PROTEIN; DIPHTHERIA TOXOID; EPITOPE;

ANTIBODY RESPONSE; ARTICLE; CELL POPULATION; DRUG CONJUGATION; DRUG SCREENING; ESCHERICHIA COLI; IMMUNE RESPONSE; IMMUNOGENICITY; INJECTION SITE; PRIORITY JOURNAL; SEROTYPE; STAPHYLOCOCCUS AUREUS; TARGET CELL;

ANIMALS; ANTIBODIES, BACTERIAL; BACTERIAL VACCINES; EPITOPES; FEMALE; IMMUNE TOLERANCE; INJECTIONS, SUBCUTANEOUS; MICE; MICE, INBRED ICR; POLYSACCHARIDES, BACTERIAL; STAPHYLOCOCCUS AUREUS; VACCINES, COMBINED; VACCINES, CONJUGATE;

EID: 0345164325     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(98)00162-5     Document Type: Article

References (42)

1. Austrian R. Some observations on the pneumococcal vaccine and on the current status of pneumococcal disease and its prevention. Reviews in Infectious Diseases. 3:1981;S51-S57.
2. Robbins J.B., Schneerson R. Polysaccharide-protein conjugates. A new generation of vaccines. Journal of Infectious Diseases. 161:1990;821-832.
3. Robbins, J.B., Schneerson, R., Egan, W.B., Vann, W. and Liu, D.T., Virulence properties of bacterial capsular polysaccharides - unanswered questions. In The Molecular Basis of Microbial Pathogenicity, eds H. Smith, J.J. Skehel and M.J. Turner. Verlag Chemie GmbH, Weinheim, 1980, pp. 115-132.
4. Fattom A.I., Sarwar J., Ortiz A., Naso R. Staphylococcus aureus capsular polysaccharide (CP) vaccine and CP-specific antibodies protect mice against bacterial challenge. Infection and Immunity. 64:1996;1659-1665.
5. Karakawa W.W., Sutton A., Schneerson R., Karpas A., Vann W.F. Capsular antibodies induce type-specific phagocytosis of capsulated Staphylococcus aureus by human polymorphonuclear leukocytes. Infection and Immunity. 56:1988;1090-1095.
6. Lee J.C., Perez N.E., Hopkins C.A., Pier G. Purified capsular polysaccharide-induced immunity to S. aureus infection. Journal of Infectious Diseases. 157:1988;723-730.
7. Robbins J.B. Vaccines for the prevention of encapsulated bacterial diseases: current status, problems and prospects for the future. Immunochemistry. 15:1978;839-854.
8. MacLeod C.M., Hodges R.G., Heidelberger M., Bernhard W.G. Prevention of pneumococcal pneumonia by immunization with specific capsular polysaccharides. Journal of Experimental Medicine. 82:1945;445-465.
9. Robbins J.B., Austrian R., Lee C.J.et al. Considerations for formulating the second generation pneumococcal vaccine with the emphasis of the cross- reactive types within groups. Journal of Infectious Diseases. 148:1983;1136-1159.
10. Bolan G., Broome C.V., Facklam R.R., Plikaytis B.D., Fraser D.W., Schlech Iii W.F. Pneumococcal vaccine efficacy in selected populations in the United States. Annals of International Medicine. 104:1986;1-6.
11. Bishop, C.T. and Jennings, H.J., Immunology of polysaccharides. In Polysaccharides, ed. G.O. Aspinal. Academic Press, New York, 1982, 1, pp. 291-330.
12. Schneerson R., Barrera O., Sutton A., Robbins J.B. Preparation, characterization and immunogenicity of Haemophilus influenzae type b polysaccharide-protein conjugates. Journal of Experimental Medicine. 152:1980;361-376.
13. Eskola J., Gordon H.K., Tapani H.et al. Simultaneous administration of Haemophilus influenzae type b capsular polysaccharide-diphtheria toxoid conjugate vaccine with routine diphtheria-tetanus-pertussis and inactivated poliovirus vaccination of childhood. Pediatric Infectious Diseases Journal. 10:1988;758-761.
14. Cross A., Artenstein A., Qu J.et al. Safety and immunogenicity of a polyvalent Escherichia coli vaccine in human volunteers. Journal of Infectious Diseases. 170:1994;834-840.
15. Sarnaik S., Kaplan J., Schiffman G., Bryla D., Robbins J.B., Schneerson R. Studies on Pneumococcus vaccine alone or mixed with DTP and on Pneumococcus type 6B and Haemophilus influenzae type b capsular polysaccharide-tetanus toxoid conjugates in two- to five-year-old children with sickle cell anemia. Pediatric Infectious Diseases. 9:1990;181-186.
16. Molrine D.C., George S., Tarbell N.et al. Antibody response to polysaccharide and polysaccharide-conjugate vaccines after treatment of Hodgkin disease. Annals of International Medicine. 123:1995;828-834.
17. Insel R.A. Potential alterations in immunogenicity by combining or simultaneously administering vaccine components. In Combined vaccines and simultaneous administration: current issues and perspectives (eds J.C. Williams, et al.). Annals of the NY Academy of Science. 754:1995;35-47.
18. Herzenberg L.A., Tukohisa T., Herzenberg L.A. Carrier-priming leads to hapten-specific suppression. Nature. 285:1980;664-667.
19. Barington T., Skettrup M., Juul L., Heilman C. Non-epitope-specific suppression of antibody response to Haemophilus influenzae type b conjugate vaccine by preimmunization with vaccine components. Infection and Immunity. 61:1993;432-438.
20. Lucak M., Pier G.B., Collier R.J. Toxin of P. aeruginosa exotoxin A generated by deletion of an active-site residue. Infection and Immunity. 56:1988;3095-3098.
21. Fattom A., Schneerson R., Szu S.C., Vann W.F., Shiloach J., Robbins J.B. Synthesis and immunologic properties in mice of vaccines composed of S. aureus type 5 and type 8 capsular polysaccharides conjugated to Pseudomonas aeruginosa exotoxin A. Infection and Immunity. 58:1990;2367-2374.
22. Fattom A., Shiloach J., Bryla D.et al. Comparative immunogenicity of conjugates composed of S. aureus type 8 capsular polysaccharide bound to carrier proteins by adipic acid dihydrazide or N-succinimidyl-3-(2-pyridyldithio) propionate. Infection and Immunity. 60:1992;584-589.
23. Chu C.Y., Schneerson R., Robbins J.B., Rastogi S.C. Further studies on the immunogenicity of Haemophilus influenzae type b and pneumococcal type 6A polysaccharide-protein conjugates. Infection and Immunity. 40:1983;245-256.
24. Cryz S.J., Cross A.S., Sadoff J.C., Furer E. Synthesis and characterization of Escherichia coli O18 O-polysaccharide conjugated vaccine. Infection and Immunity. 58:1990;373-377.
25. Chu C., Liu B., Watson D.et al. Preparation, characterization, and immunogenicity of conjugates composed of the O-specific polysaccharide of Shigella dysenteriae type 1 (Shiga's bacillus) bound to tetanus toxoid. Infection and Immunity. 59:1991;4450-4458.
26. Sutton A., Vann W., Karpas A., Stein K.E., Schneerson R. An avidin-biotin based ELISA for quantitation of antibody to bacterial polysaccharides. Journal of Immunology Methods. 82:1985;215-224.
27. Zollinger W.D., Boslego J.W. A general approach to standardization of the solid-phase radioimmunoassay for quantitation of class-specific antibodies. Journal of Immunology Methods. 46:1981;129-140.
28. Peltola H., Kayty H., Sivonen A., Makela P.H. Haemophilus influenzae type b capsular polysaccharide vaccine in children: a double-blinded field study of 100 000 vaccinees 3 months to 5 years of age in Finland. Pediatrics. 60:1977;730-737.
29. Koskela M., Leinonen M., Haiva V.M., Timonen M., Makela P.H. First and second dose antibody response to pneumococcal polysaccharide vaccine in infants. Pediatric Infectious Diseases. 5:1986;45-50.
30. Fattom A., Schneerson R., Karakawa W.W.et al. Laboratory and Clinical evaluation of conjugate vaccines composed of S. aureus types 5 and 8 capsular polysaccharides bound to Pseudomonas aeruginosa recombinant exoprotein A. Infection and Immunity. 61:1993;1023-1032.
31. Fattom A., Lue C., Szu S.C.et al. Immune response in adult volunteers elicited by injection of the Streptococcus pneumoniae type 12F polysaccharide alone or conjugated to diphtheria toxoid. Infection and Immunity. 58:1990;2309-2312.
32. Manca F., Fenoglio D., Li-Pira G., Kunkl A., Celada F. Effect of antigen/antibody ratio on macrophage uptake, processing, and presenting to T cells of antigen complexed with polyclonal antibodies. Journal of Experimental Medicine. 173:1991;37-48.
33. 197. Infection and Immunity. 39:1983;233-238.
34. Kurika S. Priming with diphtheria-tetanus-pertussis vaccine enhances the response to the Haemophilus influenzae type b tetanus conjugate vaccine in infancy. Vaccine. 14:1996;1239-1242.
35. Barington T., Gyhrs A., Kristensen K., Heilmann C. Opposite effect of actively and passively acquired immunity to the carrier on response of human infants to Haemophilus influenzae type b conjugate vaccine. Infection and Immunity. 62:1994;9-14.
36. Peeters C.C., Tenbergen-Meeks A.M., Poolman J.T., Beurret M., Zegers B.J.M., Rijkers G.T. Effect of carrier priming on immunogenicity of saccharide-protein conjugate vaccines. Infection and Immunity. 59:1991;3504-3510.
37. Sarvas H., Makela O., Toivanen P., Toivanen A. Effect of carrier preimmunization on the anti-hapten response in chicken. Scandinavian Journal of Immunology. 3:1974;455-460.
38. Scheifele D., Barreto L., Meekison W., Guasparini R., Friesen B. Can Haemophilus influenzae type b-tetanus toxoid conjugate vaccine be combined with diphtheria toxoid-pertussis vaccine-tetanus toxoid. Canadian Medical Association Journal. 149:1993;1105-1112.
39. Paradiso P.R., Hogerman D.A., Madore D.V.et al. Safety and immunogenicity of a combined diphtheria, tetanus, pertussis and Haemophilus influenzae type b vaccine in young infants. Pediatrics. 92:1993;827-832.
40. Ahman H., Kahty H., Tamminen P., Vuorela A., Malinoski F., Eskola J. Pentavalent pneumococcal polysaccharide conjugate vaccine PncCRM is well tolerated and able to induce an antibody response in infants. Pediatric Infectious Diseases Journal. 15:1996;134-139.
41. Pichichro E.M., Shelly M.A., Treanor J.J. Evaluation of pentavalent conjugated pneumococcal vaccine in toddlers. Pediatric Infectious Diseases Journal. 16:1997;72-74.
42. Shelly M.A., Jacoby H., Riley G.J., Graves B.T., Pichichero M., Treanor J.J. Comparison of pneumococcal polysaccharide and CRM 197 conjugated pneumococcal oligosaccharide vaccines in young and elderly adults. Infection and Immunity. 65:1997;242-247.